University of Turku, Dept of Biochemistry and Food Chemistry
Turku, FI-20014, Finland
NCT Number: NCT01860547
The study hypothesis is that the bioactive compounds of sea buckthorn berries (Hippophaë rhamnoides), their fractions, and bilberries (Vaccinium myrtillus). have positive effects on lipid and carbohydrate metabolism and will thus reduce the risk of developing metabolic diseases.
Looking for future studies?
Notify Me30 year–55 year
Female
Interventional
Not applicable
Turku, FI-20014, Finland
The aim of the project was to investigate whether it is possible to reduce the risk of metabolic diseases with supplementing the diet with sea buckthorn berries (Hippophaë rhamnoides), their bioactive fractions, and bilberries (Vaccinium myrtillus). The study design was a randomized cross-over clinical trial. The participants were slightly and moderately overweight female subjects. In total, 110 female volunteers were recruited, and they followed four different berry diets (bilberry, sea buckthorn, sea buckthorn phenolic extract and sea buckthorn oil) in a randomized order for 33-35 days. Each intervention was followed by a wash-out period of 30-39 days. Blood samples were drawn and physical measurements were performed after each period. Eighty volunteers completed the study. Different markers of lipid and carbohydrate metabolism and inflammation were measured form the blood samples.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Frozen bilberries, 100 g/d
Dried sea buckthorn berries, 20 g/d
Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
Sea buckthorn oil, 4 g (8 capsules)/d
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginnig to end of each berry treatment (duration of treatments average 33-35 days)
Time frame: Change from beginning to end of each berry treatment (duration of treatments average 33-35 days)
University of Turku
Other
The Effect of the Bioactives of Sea Buckthorn and Bilberry on the Risk of Metabolic Diseases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT00534014
Arterial Occlusive Diseases, Arteriosclerosis
Albuquerque, New Mexico, United States
View Trial DetailsNCT00657943
Arterial Occlusive Diseases, Arteriosclerosis
Copenhagen, Denmark
View Trial DetailsNCT01099865
Arterial Occlusive Diseases, Arteriosclerosis
Seoul, South Korea
View Trial Details